Symbols

VALN

Valneva·NASDAQ

--(--)

VALN Profile

Valneva Se

An innovative biotech company that develops prophylactic vaccines for deadly and infectious diseases

Industry

Biological Technology

Established Date

03/24/1999

Listing Date

05/06/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

674

Fiscal Year Ends

12-31

Website

www.valneva.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Ilot Saint-Joseph Bureaux Convergence Bat. A 12 ter Quai Perrache 69002 Lyon France

Business

Introduction

Valneva SE was incorporated in France on March 24, 1999. The company is a specialty vaccine company focused on the development, manufacture and commercialization of preventive vaccines for infectious diseases. The company takes a highly specialized and targeted approach to vaccine research and development, focusing on vaccine solutions that address unmet needs to ensure that people's lives are transformed. The company uses a deep understanding of vaccine science, including expertise in multiple vaccine models, and established vaccine development capabilities to develop vaccines for diseases that are not yet preventable by vaccines or have limited effective treatment options. The company's current clinical portfolio consists of a number of highly differentiated vaccine candidates designed to provide preventive solutions for diseases with high unmet needs. VLA 1553 targets chikungunya virus and is the first and currently the only chikungunya virus vaccine candidate to publish positive top-line data from a phase III clinical trial, and the first vaccine candidate to submit a Biologics Licensing Application (BLA) to the U.S. Food and Drug Administration (FDA).